JP2018512451A5 - - Google Patents

Info

Publication number

JP2018512451A5

JP2018512451A5 JP2018500860A JP2018500860A JP2018512451A5 JP 2018512451 A5 JP2018512451 A5 JP 2018512451A5 JP 2018500860 A JP2018500860 A JP 2018500860A JP 2018500860 A JP2018500860 A JP 2018500860A JP 2018512451 A5 JP2018512451 A5 JP 2018512451A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

biotin

composition according

treatment

oral administration

Prior art date

2016-03-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 40
• 239000008194 pharmaceutical composition Substances 0.000 claims 25
• 229960002685 biotin Drugs 0.000 claims 20
• 235000020958 biotin Nutrition 0.000 claims 20
• 239000011616 biotin Substances 0.000 claims 20
• 239000003814 drug Substances 0.000 claims 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
• 230000003210 demyelinating effect Effects 0.000 claims 4
• 208000008795 neuromyelitis optica Diseases 0.000 claims 4
• 238000000926 separation method Methods 0.000 claims 4
• 230000002123 temporal effect Effects 0.000 claims 4
• 108060003951 Immunoglobulin Proteins 0.000 claims 3
• 102000018358 immunoglobulin Human genes 0.000 claims 3
• 239000000203 mixture Substances 0.000 claims 3
• 201000001119 neuropathy Diseases 0.000 claims 3
• 230000007823 neuropathy Effects 0.000 claims 3
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
• 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
• 206010029240 Neuritis Diseases 0.000 claims 2
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 2
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
• 229960000836 amitriptyline Drugs 0.000 claims 2
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
• 229960002170 azathioprine Drugs 0.000 claims 2
• 229960000794 baclofen Drugs 0.000 claims 2
• 230000001684 chronic effect Effects 0.000 claims 2
• 239000003246 corticosteroid Substances 0.000 claims 2
• 229960001334 corticosteroids Drugs 0.000 claims 2
• 229960004397 cyclophosphamide Drugs 0.000 claims 2
• 229960003529 diazepam Drugs 0.000 claims 2
• 229960003776 glatiramer acetate Drugs 0.000 claims 2
• 230000002757 inflammatory effect Effects 0.000 claims 2
• 238000001990 intravenous administration Methods 0.000 claims 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
• 229960001156 mitoxantrone Drugs 0.000 claims 2
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
• 229960004866 mycophenolate mofetil Drugs 0.000 claims 2
• 208000033808 peripheral neuropathy Diseases 0.000 claims 2
• 239000008177 pharmaceutical agent Substances 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 229960004181 riluzole Drugs 0.000 claims 2
• -1 rituximab Chemical compound 0.000 claims 2
• 229960004641 rituximab Drugs 0.000 claims 2
• 229960001032 trihexyphenidyl Drugs 0.000 claims 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
• 102000003886 Glycoproteins Human genes 0.000 claims 1
• 108090000288 Glycoproteins Proteins 0.000 claims 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
• 102000006386 Myelin Proteins Human genes 0.000 claims 1
• 108010083674 Myelin Proteins Proteins 0.000 claims 1
• 239000004480 active ingredient Substances 0.000 claims 1
• 229940124324 agent for amyotrophic lateral sclerosis Drugs 0.000 claims 1
• 239000002775 capsule Substances 0.000 claims 1
• 230000018044 dehydration Effects 0.000 claims 1
• 238000006297 dehydration reaction Methods 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 239000008101 lactose Substances 0.000 claims 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
• 239000008108 microcrystalline cellulose Substances 0.000 claims 1
• 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
• 210000005012 myelin Anatomy 0.000 claims 1
• 239000006187 pill Substances 0.000 claims 1
• 238000013268 sustained release Methods 0.000 claims 1
• 239000012730 sustained-release form Substances 0.000 claims 1
• 239000000454 talc Substances 0.000 claims 1
• 229910052623 talc Inorganic materials 0.000 claims 1